Difference between revisions of "Thiotepa (Thioplex)"
m |
m (→References) |
||
| Line 23: | Line 23: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Intracavitary chemotherapy]] | ||
| + | [[Category:Intrathecal chemotherapy]] | ||
| + | [[Category:Intravenous chemotherapy]] | ||
| + | [[Category:Intravesicular chemotherapy]] | ||
| + | |||
[[Category:Alkylating agents]] | [[Category:Alkylating agents]] | ||
Revision as of 20:39, 11 December 2014
Also known as TESPA, Thiophosphoamide, or TSPA.
General information
Class/mechanism: Alkylator, ethylenimine-type, similar to nitrogen mustards. Ethylenimine radicals are released, which alkylates at the N7 position of guanine, resulting in the linkage between the purine and sugar being severed, and subsequent cell damage and death.[1][2]
Route: IV, intravesicular, intracavitary; (off-label: IT)
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Thiotepa (Thioplex) patient drug information (Chemocare)[3]
- Thiotepa (Thioplex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 3/9/1959: Initial FDA approval